We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Axon (AXON) Reports Q2 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Axon Enterprise (AXON - Free Report) reported $374.61 million in revenue for the quarter ended June 2023, representing a year-over-year increase of 31.2%. EPS of $1.11 for the same period compares to $0.44 a year ago.
The reported revenue represents a surprise of +7.79% over the Zacks Consensus Estimate of $347.53 million. With the consensus EPS estimate being $0.62, the EPS surprise was +79.03%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Axon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Annual recurring revenue: $559 compared to the $548.43 average estimate based on three analysts.
Revenue- TASER: $154.41 million versus the four-analyst average estimate of $147.76 million. The reported number represents a year-over-year change of +13.9%.
Net Sales- Software and Sensors: $220.20 million versus the four-analyst average estimate of $199.77 million. The reported number represents a year-over-year change of +46.8%.
Net Sales- Services- TASER: $8.49 million compared to the $6.50 million average estimate based on two analysts. The reported number represents a change of +119.8% year over year.
Net Sales- Products- Software and Sensors: $87.56 million compared to the $83.78 million average estimate based on two analysts. The reported number represents a change of +28.1% year over year.
Net Sales- Products- TASER: $145.92 million versus $144.90 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.
Net Sales- Services- Software and Sensors: $132.64 million versus the two-analyst average estimate of $112.75 million. The reported number represents a year-over-year change of +62.4%.
Gross Margin- Software and Sensors: $138.76 million versus $117.33 million estimated by four analysts on average.
Gross Margin- TASER: $93.36 million versus $90.42 million estimated by three analysts on average.
Shares of Axon have returned -8% over the past month versus the Zacks S&P 500 composite's +2.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Axon (AXON) Reports Q2 Earnings: What Key Metrics Have to Say
Axon Enterprise (AXON - Free Report) reported $374.61 million in revenue for the quarter ended June 2023, representing a year-over-year increase of 31.2%. EPS of $1.11 for the same period compares to $0.44 a year ago.
The reported revenue represents a surprise of +7.79% over the Zacks Consensus Estimate of $347.53 million. With the consensus EPS estimate being $0.62, the EPS surprise was +79.03%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Axon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Annual recurring revenue: $559 compared to the $548.43 average estimate based on three analysts.
- Revenue- TASER: $154.41 million versus the four-analyst average estimate of $147.76 million. The reported number represents a year-over-year change of +13.9%.
- Net Sales- Software and Sensors: $220.20 million versus the four-analyst average estimate of $199.77 million. The reported number represents a year-over-year change of +46.8%.
- Net Sales- Services- TASER: $8.49 million compared to the $6.50 million average estimate based on two analysts. The reported number represents a change of +119.8% year over year.
- Net Sales- Products- Software and Sensors: $87.56 million compared to the $83.78 million average estimate based on two analysts. The reported number represents a change of +28.1% year over year.
- Net Sales- Products- TASER: $145.92 million versus $144.90 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.
- Net Sales- Services- Software and Sensors: $132.64 million versus the two-analyst average estimate of $112.75 million. The reported number represents a year-over-year change of +62.4%.
- Gross Margin- Software and Sensors: $138.76 million versus $117.33 million estimated by four analysts on average.
- Gross Margin- TASER: $93.36 million versus $90.42 million estimated by three analysts on average.
View all Key Company Metrics for Axon here>>>Shares of Axon have returned -8% over the past month versus the Zacks S&P 500 composite's +2.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.